Dashboard
Manage Tickers

TPST


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
09/04/2025 21:13:45

tempest-therapeutics-q2-eps-207-beats-323-estimate
Tempest Therapeutics Q2 EPS $(2.07) Beats ...
08/11/2025 20:22:58

Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(2.07) per share which beat the analyst consensus estimate of ...

tempest-announces-46m-registered-direct-offering-of-common-stock-739000-shares-at-625-per-share
Tempest Announces $4.6M Registered Direct ...
06/11/2025 12:11:03

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
06/11/2025 12:07:40

why-circle-internet-group-shares-are-trading-higher-by-around-18-here-are-20-stocks-moving-premarket
Why Circle Internet Group Shares Are Tradi...
06/09/2025 12:46:39

Core News & Articles
12 Health Care Stocks Moving In Monday's P...
06/09/2025 12:08:42

tempest-announces-it-has-received-orphan-drug-designation-from-european-medicines-agency-for-its-amezalpat-for-treatment-of-patients-with-hepatocellular-carcinoma
Tempest Announces It Has Received Orphan D...
06/05/2025 12:08:01

EMA Orphan Drug Designation (ODD) builds on U.S. Food & Drug Administration (FDA) ODD and Fast Track Designation, underscor...

tempest-therapeutics-q1-eps-316-beats-371-estimate
Tempest Therapeutics Q1 EPS $(3.16) Beats ...
05/13/2025 20:45:29

Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(3.16) per share which beat the analyst consensus estimate of ...

tempest-presents-new-amezalpat-moa-data-supporting-its-potential-as-novel-cancer-treatment-at-the-2025-aacr-annual-meeting
Tempest Presents New Amezalpat MOA Data Su...
04/28/2025 20:07:01

tempest-receives-fda-orphan-drug-designation-for-tpst-1495-to-treat-patients-with-familial-adenomatous-polyposis
Tempest Receives FDA Orphan Drug Designati...
04/21/2025 12:01:19

tempest-weighs-ma-analyst-sees-a-broken-story-despite-phase-2-liver-cancer-study-success
Tempest Weighs M&A, Analyst Sees A "Broken...
04/10/2025 16:00:40

Tempest Therapeutics hires MTS Health to explore M&A and partnerships after Roche shows limited interest in its liver cance...

correction--scotiabank-downgrades-tempest-therapeutics-to-sector-perform-raises-price-target-to-9-previous-target-changed
Correction : Scotiabank Downgrades Tempest...
04/10/2025 12:27:25

Correction: Scotiabank analyst George Farmer downgrades Tempest Therapeutics (NASDAQ:TPST) from Sector Outperform to Sector Per...

hc-wainwright--co-downgrades-tempest-therapeutics-to-neutral-maintains-price-target-to-16
HC Wainwright & Co. Downgrades Tempest The...
04/10/2025 10:48:04

HC Wainwright & Co. analyst Joseph Pantginis downgrades Tempest Therapeutics (NASDAQ:TPST) from Buy to Neutral and maint...

tempest-therapeutics-plans-to-explore-strategic-alternatives-to-advance-promising-clinical-stage-programs-and-maximize-stockholder-value
Tempest Therapeutics Plans to Explore Stra...
04/09/2025 20:35:18

Amezalpat (TPST-1120) is Phase 3-ready: completed FDA and EMA interactions for first-line pivotal study in hepatocellular carci...

trading-halt-halt-status-updated-at-85500-am-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 8:55:...
04/09/2025 12:55:04

trading-halt-halted-at-75000-pm-et---trading-halt-halt-news-pending
Trading Halt: Halted at 7:50:00 p.m. ET - ...
04/08/2025 23:50:04

scotiabank-maintains-sector-outperform-on-tempest-therapeutics-lowers-price-target-to-7
Scotiabank Maintains Sector Outperform on ...
03/28/2025 14:36:33

Scotiabank analyst George Farmer maintains Tempest Therapeutics (NASDAQ:TPST) with a Sector Outperform and lowers the price ...

hc-wainwright--co-maintains-buy-on-tempest-therapeutics-lowers-price-target-to-16
HC Wainwright & Co. Maintains Buy on Tempe...
03/28/2025 11:35:29

HC Wainwright & Co. analyst Joseph Pantginis maintains Tempest Therapeutics (NASDAQ:TPST) with a Buy and lowers the pric...

tempest-therapeutics-fy-2024-gaap-eps-150-misses-138-estimate
Tempest Therapeutics FY 2024 GAAP EPS $(1....
03/27/2025 20:25:07

Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(1.50) per share which missed the analyst consensus estimate o...

tempest-therapeutics-announces-the-cancer-prevention-clinical-trials-network-received-fda-study-may-proceed-letter-for-phase-2-trial-of-tpst-1495
Tempest Therapeutics Announces The Cancer ...
03/13/2025 12:00:53

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION